Dexcom’s New Clinician Academy: A Subtle Shift in DXCM’s Long‑Term Competitive Moat?

Simply Wall St.

2025/12/15

Earlier this month, Dexcom launched Dexcom Academy across several EMEA markets, offering personalised, app-based training for healthcare professionals on its CGM products and broader diabetes care. ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2591669761"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591669761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591669761?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2025-12-15 12:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591669761","market":"hk","top_or_hot":-1,"title":"Dexcom’s New Clinician Academy: A Subtle Shift in DXCM’s Long‑Term Competitive Moat?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Dexcom launched Dexcom Academy across several EMEA markets, offering personalised, app-based training for healthcare professionals on its CGM products and broader diabetes care. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/dexcoms-new-clinician-academy-a-subtle-shift-in-dxcms-longte\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dexcom’s New Clinician Academy: A Subtle Shift in DXCM’s Long‑Term Competitive Moat?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDexcom’s New Clinician Academy: A Subtle Shift in DXCM’s Long‑Term Competitive Moat?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-12-15 12:28</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Earlier this month, Dexcom launched Dexcom Academy across several EMEA markets, offering personalised, app-based training for healthcare professionals on its CGM products and broader diabetes care. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/dexcoms-new-clinician-academy-a-subtle-shift-in-dxcms-longte\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/dexcoms-new-clinician-academy-a-subtle-shift-in-dxcms-longte\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125909593.SGD","symbol_name":"Natixis Thematics Meta R/A SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/dexcoms-new-clinician-academy-a-subtle-shift-in-dxcms-longte","article_id":"2591669761","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/dexcoms-new-clinician-academy-a-subtle-shift-in-dxcms-longte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591669761","pubTimestamp":1765772932,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Dexcom launched Dexcom Academy across several EMEA markets, offering personalised, app-based training for healthcare professionals on its CGM products and broader diabetes care.\nThis education platform, co-created with clinicians and focused on practical, consultation-ready content, signals Dexcom’s effort to deepen CGM adoption while easing clinical workloads.\nWe’ll now examine how this push into clinician-focused education could influence Dexcom’s longer-term investment...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4082":"医疗保健设备","BK4504":"桥水持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","DXCM":"德康医疗","BK4588":"碎股","BK4548":"巴美列捷福持仓","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4551":"寇图资本持仓","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC"},"translate_title":"Dexcom的新临床医生学院：DXCM长期竞争护城河的微妙转变？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1.5},"content_text":"Earlier this month, Dexcom launched Dexcom Academy across several EMEA markets, offering personalised, app-based training for healthcare professionals on its CGM products and broader diabetes care. This education platform, co-created with clinicians and focused on practical, consultation-ready content, signals Dexcom’s effort to deepen CGM adoption while easing clinical workloads. We’ll now examine how this push into clinician-focused education could influence Dexcom’s longer-term investment narrative and growth ambitions. We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.DexCom Investment Narrative RecapTo own DexCom, you generally need to believe that continuous glucose monitoring remains central to diabetes care and that DexCom can keep expanding adoption across both Type 1 and Type 2 patients. Near term, the key catalyst is uptake of the new 15 day G7 sensor, while the securities class action tied to alleged G6/G7 reliability issues is a clear risk; the Dexcom Academy launch itself does not materially change either. Among recent developments, the US launch of the G7 15 Day CGM system stands out as most relevant. If clinicians in EMEA become more comfortable with CGM through Dexcom Academy, that education effort could indirectly support broader product adoption over time, including next generation sensors like G7 15 Day, which many investors are watching closely as a driver of DexCom’s growth ambitions. Yet against this product and education momentum, the emerging lawsuit over alleged design changes and device reliability is something investors should be aware of and... Read the full narrative on DexCom (it's free!)DexCom's narrative projects $6.5 billion revenue and $1.4 billion earnings by 2028.Uncover how DexCom's forecasts yield a $84.31 fair value, a 26% upside to its current price.Exploring Other PerspectivesDXCM 1-Year Stock Price Chart Seven members of the Simply Wall St Community value DexCom between US$84.31 and US$127.89, reflecting a wide span of expectations. Against that, concerns about potential CMS competitive bidding and pricing pressure could meaningfully shape how the company’s actual performance compares with these views, so it is worth weighing several perspectives before forming your own.Explore 7 other fair value estimates on DexCom - why the stock might be worth just $84.31!Build Your Own DexCom NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your DexCom research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.Want Some Alternatives?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Find companies with promising cash flow potential yet trading below their fair value.Uncover the next big thing with financially sound penny stocks that balance risk and reward.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}